Research Digest

Lab notes: Use of the female contraceptive DMPA may increase risk of HIV infection

New analysis indicates that the hormonal contraceptive be replaced with other formulations or methods.

A new review of research suggests that women using the injectable contraceptive depot-medroxyprogesterone acetate or DMPA might be at higher risk of HIV infection by as much at 40%.

Medical researchers at the University of Alabama at Birmingham in the United States, the University of Cape Town in South Africa and McMaster University in Canada examined the underlying biological mechanisms that could contribute to greater risk of HIV infection for certain hormonal contraceptives. They also examined animal, cell and biochemical research on medroxyprogesterone acetate, which is the main component of DMPA, to find that it acts differently from other forms of progestin used in contraceptives. In the cells of the genital tract that can come in contact with HIV, medroxyprogesterone acetate behaves like the stress hormone cortisol, which is an immunosuppressant, possibly causing decreases in immune function and interfering with the protective barrier function of the female genital tract.

The researchers say that the findings offer an explanation as to why there has been an increased rate of HIV infection. New formulations that administer 31% less hormone to offset the immunosuppressive effect of DMPA have been tested but it has been found the authors of the review conclude that even though it is likely to result in a partial reduction of concentration of the hormone shortly after delivery, it is not likely to ameliorate the overall negative impact of medroxyprogesterone on biological responses.

The authors suggest that other forms of birth control should rapidly replace DMPA shots. They also emphasise that DMPA should be replaced and not just removed from shelves so that women in sub-Saharan Africa and other high risk regions where DMPA is used are not left without contraceptive options. DMPA is used by an estimated 50 million women worldwide. India introduced DMPA into its family planning programme in July 2017, despite the objection of health activists who pointed to possible side effects and the manner in which full information will be given and informed consent received from large numbers of poorly educated women that the programme targets.

The study was published in the journal Endocrine Reviews.

Support our journalism by subscribing to Scroll+ here. We welcome your comments at
Sponsored Content BY 

Following a mountaineer as he reaches the summit of Mount Everest

Accounts from Vikas Dimri’s second attempt reveal the immense fortitude and strength needed to summit the Everest.

Vikas Dimri made a huge attempt last year to climb the Mount Everest. Fate had other plans. Thwarted by unfavourable weather at the last minute, he came so close and yet not close enough to say he was at the top. But that did not deter him. Vikas is back on the Everest trail now, and this time he’s sharing his experiences at every leg of the journey.

The Everest journey began from the Lukla airport, known for its dicey landing conditions. It reminded him of the failed expedition, but he still moved on to Namche Bazaar - the staging point for Everest expeditions - with a positive mind. Vikas let the wisdom of the mountains guide him as he battled doubt and memories of the previous expedition. In his words, the Everest taught him that, “To conquer our personal Everest, we need to drop all our unnecessary baggage, be it physical or mental or even emotional”.

Vikas used a ‘descent for ascent’ approach to acclimatise. In this approach, mountaineers gain altitude during the day, but descend to catch some sleep. Acclimatising to such high altitudes is crucial as the lack of adequate oxygen can cause dizziness, nausea, headache and even muscle death. As Vikas prepared to scale the riskiest part of the climb - the unstable and continuously melting Khumbhu ice fall - he pondered over his journey so far.

His brother’s diagnosis of a heart condition in his youth was a wakeup call for the rather sedentary Vikas, and that is when he started focusing on his health more. For the first time in his life, he began to appreciate the power of nutrition and experimented with different diets and supplements for their health benefits. His quest for better health also motivated him to take up hiking, marathon running, squash and, eventually, a summit of the Everest.

Back in the Himalayas, after a string of sleepless nights, Vikas and his team ascended to Camp 2 (6,500m) as planned, and then descended to Base Camp for the basic luxuries - hot shower, hot lunch and essential supplements. Back up at Camp 2, the weather played spoiler again as a jet stream - a fast-flowing, narrow air current - moved right over the mountain. Wisdom from the mountains helped Vikas maintain perspective as they were required to descend 15km to Pheriche Valley. He accepted that “strength lies not merely in chasing the big dream, but also in...accepting that things could go wrong.”

At Camp 4 (8,000m), famously known as the death zone, Vikas caught a clear glimpse of the summit – his dream standing rather tall in front of him.

It was the 18th of May 2018 and Vikas finally reached the top. The top of his Everest…the top of Mount Everest!

Watch the video below to see actual moments from Vikas’ climb.


Vikas credits his strength to dedication, exercise and a healthy diet. He credits dietary supplements for helping him sustain himself in the inhuman conditions on Mount Everest. On heights like these where the oxygen supply drops to 1/3rd the levels on the ground, the body requires 3 times the regular blood volume to pump the requisite amount of oxygen. He, thus, doesn’t embark on an expedition without double checking his supplements and uses Livogen as an aid to maintain adequate amounts of iron in his blood.

Livogen is proud to have supported Vikas Dimri on his ambitious quest and salutes his spirit. To read more about the benefits of iron, see here. To read Vikas Dimri’s account of his expedition, click here.

This article was produced by the Scroll marketing team on behalf of Livogen and not by the Scroll editorial team.